HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical management of beta-thalassemia major.

Abstract
Management of patients with beta-thalassemia is based on adequate, safe blood transfusions (free of transfusion-transmitted diseases) and prevention of iron overload. Iron overload causes multiple endocrinopathies, contributes to osteoporosis, and is the cause of cardiac disease. Cardiac disease, secondary to iron damage, causes death in developed countries as a result of noncompliance to deferoxamine from the third decade of life. In underdeveloped countries, cardiac death starts from 12 years of age, due to nonavailability of deferoxamine. With the emergence of the advanced cardiac magnetic resonance imaging technique, early diagnosis of heart iron will allow the currently available iron-chelating agents (oral and parenteral) to be used in an innovative way to improve the quality of life and improve survival of patients with beta-thalassemia.
AuthorsB Wonke
JournalSeminars in hematology (Semin Hematol) Vol. 38 Issue 4 Pg. 350-9 (Oct 2001) ISSN: 0037-1963 [Print] United States
PMID11605170 (Publication Type: Journal Article, Review)
CopyrightCopyright 2001 by W.B. Saunders Company.
Topics
  • Disease Management
  • Disease Progression
  • Female
  • Forecasting
  • Humans
  • Infections (drug therapy, etiology)
  • Male
  • Pregnancy
  • Transfusion Reaction
  • beta-Thalassemia (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: